GKOS (Glaukos) LT-Debt-to-Total-Asset : 0.11 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Glaukos LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Glaukos's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.11.

Glaukos's long-term debt to total assets ratio declined from Dec. 2023 (0.41) to Dec. 2024 (0.11). It may suggest that Glaukos is progressively becoming less dependent on debt to grow their business.

Glaukos LT-Debt-to-Total-Asset Historical Data

The historical data trend for Glaukos's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos LT-Debt-to-Total-Asset Chart

Glaukos Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.27

0.36

0.38

0.41

0.11

Glaukos Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.41	0.41	0.17	0.17	0.11

Glaukos LT-Debt-to-Total-Asset Calculation

Glaukos's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	103.399	/	974.756
	=	0.11

Glaukos's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	103.399	/	974.756
	=	0.11

Glaukos (NYSE:GKOS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Glaukos LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Glaukos's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Glaukos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

6GJ:Germany

Address

One Glaukos Way, Aliso Viejo, CA, USA, 92656

Website

https://www.glaukos.com

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Executives

Mark J Foley	director	ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tomas Navratil	officer: Chief Development Officer	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Gilbert H Kliman	director	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Joseph E Gilliam	officer: CFO, SVP Corporate Development	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Marc Stapley	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Aimee S Weisner	director	ONE EDWARDS WAY, IRVINE CA 92614
Alex R. Thurman	officer: SVP & Chief Financial Officer	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Thomas William Burns	director, 10 percent owner, officer: Chief Executive Officer	C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Denice Torres	director	3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Leana Wen	director	C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Chris M. Calcaterra	officer: Chief Commercial Officer	C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan Silverstein	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison	officer: Treasurer, CFO & Secretary	26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653